2017 ACR/ARHP Annual Meeting

November 3-8, 2017. San Diego, CA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 841

Optimal Regimens of Sulfamethoxazole-Trimethoprim for Chemoprophylaxis of Pneumocystis Pneumonia in Patients with Systemic Rheumatic Diseases: 52-Week Follow-up of a Non-Blinded, Randomized Controlled Trial
Abstract Number: 705

Optimization of a Cost-Effective Diagnostic ANA Algorithm
Abstract Number: 2854

Optimizing Data Capture for Performance – Metrics Using Smartphone App Technology
Abstract Number: 172

Optimizing Precision Medicine By Using Genetics to Assign Diagnostic Prior Probabilities to Patients with Synovitis
Abstract Number: 1313

Oral Corticosteroid Use during Pregnancy and Risk of Preterm Birth in Women with Rheumatoid Arthritis
Abstract Number: 1190

Orosomucoid 2 Serves As Predictor of Therapeutic Response in Osteoarthritis Patients Treated with Chondroitin Sulfate/Glucosamine Hydrochloride
Abstract Number: 2900

Osteoarthritis-Associated Calcium-Containing Crystals and Biomaterial Microparticles Both Drive M1 Macrophage Polarization in a Syk and MAP Kinase-Dependent Manner
Abstract Number: 1899

Osteopontin and Leptin Are Associated with Erosive Disease in an Inception Cohort of Rheumatoid Arthritis Treated-to-Target with Combination Conventional DMARD Therapy
Abstract Number: 1227

Osteoporosis and Breast Cancer: Can FRAX-Based Risk Factors Accurately Predict Further Fractures at This Setting?
Abstract Number: 326

Osteoporosis and Vertebral Fractures Are Associated with Disease Activity, Low Vitamin D Levels and Spinal Radiographic Damage in Patients with Axial Spondyloarthritis
Abstract Number: 2940

Outcome of Power Doppler Ultrasound-Detected Residual Synovitis in Rheumatoid Arthritis Patients with Clinical Remission: A 1 Year Longitudinal Study with Consecutive Ultrasound Examinations
Abstract Number: 303

Outcomes after Hip Fracture in the Elderly: Does Social Isolation Matter?
Abstract Number: 1250

Outcomes in Real-World Patients with Early Aggressive Rheumatoid Arthritis
Abstract Number: 2922

Outcomes of Lupus Nephritis in Vulnerable Populations
Abstract Number: 2485

Outcomes of Switching from TNF Inhibitors to Subcutaneous Golimumab in Patients with Rheumatoid Arthritis to Control Disease Activity or Adverse Events

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].